143,965 Shares in Novavax, Inc. (NVAX) Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC bought a new stake in Novavax, Inc. (NASDAQ:NVAX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 143,965 shares of the biopharmaceutical company’s stock, valued at approximately $179,000.

Several other institutional investors and hedge funds have also made changes to their positions in NVAX. Nationwide Fund Advisors raised its position in shares of Novavax by 555.1% in the 2nd quarter. Nationwide Fund Advisors now owns 1,024,020 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 867,700 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Novavax by 39.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,153,971 shares of the biopharmaceutical company’s stock valued at $1,328,000 after purchasing an additional 326,415 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Novavax by 14.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,391,610 shares of the biopharmaceutical company’s stock valued at $1,600,000 after purchasing an additional 176,510 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Novavax by 39.8% in the 2nd quarter. Alliancebernstein L.P. now owns 425,701 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 121,200 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Novavax by 30.8% in the 3rd quarter. Wells Fargo & Company MN now owns 446,831 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 105,117 shares in the last quarter. 35.69% of the stock is currently owned by institutional investors.

In related news, insider Stanley C. Erck bought 100,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were purchased at an average cost of $1.13 per share, with a total value of $113,000.00. Following the completion of the transaction, the insider now directly owns 228,279 shares of the company’s stock, valued at $257,955.27. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is owned by company insiders.

Shares of Novavax, Inc. (NVAX) opened at $2.00 on Monday. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31. The stock has a market capitalization of $627.23, a P/E ratio of -2.94 and a beta of 2.68. Novavax, Inc. has a 52-week low of $0.73 and a 52-week high of $2.32.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. The firm had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.42 million. The business’s revenue was up 158.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.24) earnings per share. research analysts predict that Novavax, Inc. will post -0.62 earnings per share for the current year.

A number of brokerages have issued reports on NVAX. S&P Equity Research cut their target price on Novavax from $1.81 to $1.35 in a research report on Wednesday, January 10th. B. Riley set a $10.00 price target on Novavax and gave the company a “buy” rating in a research report on Thursday, January 11th. Ladenburg Thalmann Financial Services upped their price target on Novavax to $2.50 and gave the company a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research lowered Novavax from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Finally, Citigroup lowered Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $2.64.

ILLEGAL ACTIVITY NOTICE: “143,965 Shares in Novavax, Inc. (NVAX) Purchased by Fisher Asset Management LLC” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2018/02/05/143965-shares-in-novavax-inc-nvax-purchased-by-fisher-asset-management-llc.html.

Novavax Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit